Abstract
Early detection and intervention are believed to be key to facilitating better outcomes in children with autism, yet the impact of age at treatment start on outcome is poorly understood. While clinical traits such as language ability have been shown to predict treatment outcome, whether or not and how information at the genomic level can predict treatment outcome is unknown. Leveraging a cohort of toddlers with autism who all received the same standardized intervention at a very young age and provided a blood sample, here we find that very early treatment engagement (i.e., < 24 months) leads to greater gains while controlling for time in treatment. Pre-treatment clinical behavioral measures predicts 21% of the variance in the rate of skill growth during early intervention. Pre-treatment blood leukocyte gene expression patterns also predicts rate of skill growth, accounting for 13% of the variance treatment slopes. Results indicated that 295 genes can be prioritized as driving this effect. These treatment-relevant genes highly interact at the protein level, are enriched for differentially histone acetylated genes in autism post-mortem cortical tissue, and are normatively highly expressed in variety of subcortical and cortical areas important for social-communication and language development. This work indicates for the first time that gene expression can predict the rate of early intervention response and that a key biological factor linked to treatment outcome could be the susceptibility for epigenetic change via mechanisms such as histone acetylation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme under grant agreement No 755816 (ERC Starting Grant to MVL). This work was also supported by the following grants to EC, KP, LE, and NEL - NIMH R01-MH080134 (KP), NIMH R01-MH104446 (KP), NFAR grant (KP), NIMH Autism Center of Excellence grant P50-MH081755 (EC, KP), NIMH R01-MH036840 (EC), NIMH R01- MH110558 (EC, NEL), NIMH U01-MH108898 (EC), NIDCD R01-DC016385 (EC, KP, LE, MVL), CDMRP AR130409 (EC), and the Simons Foundation 176540 (EC).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Institutional Review Board at the University of California, San Diego
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Analysis code is available at https://github.com/IIT-LAND/gex_treatment_slopes. Data are available from the National Institute of Mental Health Data Archive (NDA) (https://nda.nih.gov). Raw and normalized blood gene expression data are also deposited in Gene Expression Omnibus (GEO) (GSE42133; GSE111175).
